Cargando…
The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model
BACKGROUND: Weight gain is one of the consequences of estrogen deficiency and constitutes a major health problem. The present study highlights the effects of N-methyl pyrrolidone (NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized rat model. RESULTS: Ovariectomy...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840488/ https://www.ncbi.nlm.nih.gov/pubmed/27110299 http://dx.doi.org/10.1186/s13148-016-0209-2 |
_version_ | 1782428288820445184 |
---|---|
author | Gjoksi, Bebeka Ghayor, Chafik Bhattacharya, Indranil Zenobi-Wong, Marcy Weber, Franz E. |
author_facet | Gjoksi, Bebeka Ghayor, Chafik Bhattacharya, Indranil Zenobi-Wong, Marcy Weber, Franz E. |
author_sort | Gjoksi, Bebeka |
collection | PubMed |
description | BACKGROUND: Weight gain is one of the consequences of estrogen deficiency and constitutes a major health problem. The present study highlights the effects of N-methyl pyrrolidone (NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized rat model. RESULTS: Ovariectomy resulted in body weight gain, increased femoral marrow adipocytes, and hypertrophic adipocytes in white adipose tissue, distorted serum leptin, and TNF-α and PPARγ levels. Treatment with NMP normalized these parameters similar to the control group. In vitro, NMP inhibited the differentiation of 3T3-L1 pre-adipocytes and hMSCs, indicating its anti-adipogenic effect. Moreover, PPARγ was significantly reduced with NMP treatment in in vivo and in vitro experiments. NMP inhibited BRD2 and BRD4 binding in an AlphaScreen assay, with an IC50 of 3 and 4 mM, respectively. The effect of NMP was consistent with its role as a bromodomain inhibitor. CONCLUSIONS: Our data indicates that NMP inhibits the adipogenic effect of estrogen deficiency at the level of PPARγ expression by BRD4 inhibition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0209-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4840488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48404882016-04-23 The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model Gjoksi, Bebeka Ghayor, Chafik Bhattacharya, Indranil Zenobi-Wong, Marcy Weber, Franz E. Clin Epigenetics Research BACKGROUND: Weight gain is one of the consequences of estrogen deficiency and constitutes a major health problem. The present study highlights the effects of N-methyl pyrrolidone (NMP) on adipogenesis in osteoporosis induced by estrogen deficiency in an ovariectomized rat model. RESULTS: Ovariectomy resulted in body weight gain, increased femoral marrow adipocytes, and hypertrophic adipocytes in white adipose tissue, distorted serum leptin, and TNF-α and PPARγ levels. Treatment with NMP normalized these parameters similar to the control group. In vitro, NMP inhibited the differentiation of 3T3-L1 pre-adipocytes and hMSCs, indicating its anti-adipogenic effect. Moreover, PPARγ was significantly reduced with NMP treatment in in vivo and in vitro experiments. NMP inhibited BRD2 and BRD4 binding in an AlphaScreen assay, with an IC50 of 3 and 4 mM, respectively. The effect of NMP was consistent with its role as a bromodomain inhibitor. CONCLUSIONS: Our data indicates that NMP inhibits the adipogenic effect of estrogen deficiency at the level of PPARγ expression by BRD4 inhibition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0209-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-22 /pmc/articles/PMC4840488/ /pubmed/27110299 http://dx.doi.org/10.1186/s13148-016-0209-2 Text en © Gjoksi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gjoksi, Bebeka Ghayor, Chafik Bhattacharya, Indranil Zenobi-Wong, Marcy Weber, Franz E. The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
title | The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
title_full | The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
title_fullStr | The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
title_full_unstemmed | The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
title_short | The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
title_sort | bromodomain inhibitor n-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840488/ https://www.ncbi.nlm.nih.gov/pubmed/27110299 http://dx.doi.org/10.1186/s13148-016-0209-2 |
work_keys_str_mv | AT gjoksibebeka thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT ghayorchafik thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT bhattacharyaindranil thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT zenobiwongmarcy thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT weberfranze thebromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT gjoksibebeka bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT ghayorchafik bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT bhattacharyaindranil bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT zenobiwongmarcy bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel AT weberfranze bromodomaininhibitornmethylpyrrolidonereducedfataccumulationinanovariectomizedratmodel |